Surrozen (SRZN) Gains from Sales and Divestitures (2021 - 2026)
Surrozen (SRZN) recorded quarterly Gains from Sales and Divestitures of $18000.0 in Q1 2026, down 5.26% quarter-over-quarter from $19000.0 in Q4 2025, and down 5.26% on a YoY basis from $19000.0 in Q1 2025.
Surrozen (SRZN) Gains from Sales and Divestitures (2021 - 2026) Analysis & Trends
Surrozen's Gains from Sales and Divestitures history runs 6 years deep, the most recent figure standing at $18000.0 for Q1 2026.
- In Q1 2026, Gains from Sales and Divestitures fell 5.26% year-over-year to $18000.0; the TTM figure through Mar 2026 stood at $18000.0 (down 5.26% YoY), while the FY2025 annual figure was $19000.0, down 78.41% from the prior year.
- Gains from Sales and Divestitures was $18000.0 for Q1 2026 at Surrozen, down from $19000.0 in the prior quarter.
- In the past five years, Gains from Sales and Divestitures ranged from a high of $88000.0 in Q4 2024 to a low of $18.0 in Q1 2022.
- Historically, Gains from Sales and Divestitures has averaged $20949.5 across 5 years, with a median of $19000.0 in 2025.
- Biggest YoY gain for Gains from Sales and Divestitures was 77319.35% in 2023; the steepest drop was 99.92% in 2023.
- A 5-year view of Gains from Sales and Divestitures shows it stood at $56.0 in 2022, then soared by 5257.14% to $3000.0 in 2023, then jumped by 2833.33% to $88000.0 in 2024, then tumbled by 78.41% to $19000.0 in 2025, then slipped by 5.26% to $18000.0 in 2026.
- The last three Gains from Sales and Divestitures figures came in at $18000.0 (Q1 2026), $19000.0 (Q4 2025), and $19000.0 (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Alterity Therapeutics | 788,338.31 Bn | 788,338.28 Bn | - |
| 2 | Belite Bio | 56,560.00 Bn | 56,560.00 Bn | - |
| 3 | Quantum Biopharma | 17,329.30 Bn | 17,329.30 Bn | - |
| 4 | Legend Biotech | 3,341.00 Bn | 3,340.71 Bn | 242.10 Mn |
| 5 | Akari Therapeutics | 1,727.91 Bn | 1,727.91 Bn | - |
| 6 | Evaxion A | 1,536.68 Bn | 1,536.67 Bn | - |
| 7 | Psyence Biomedical | 238.34 Bn | 238.33 Bn | - |
| 8 | Vertex Pharmaceuticals | 113.42 Bn | 106.17 Bn | 2.59 Bn |
| 9 | Abivax | 95.45 Bn | 95.45 Bn | - |
| 10 | Surrozen | 239,016.67 | -106.67 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 18,000.00 |
| Mar 31, 2026 | 18,000.00 |
| Dec 31, 2025 | 19,000.00 |
| Dec 31, 2025 | 19,000.00 |
| Sep 30, 2025 | 19,000.00 |
| Sep 30, 2025 | 19,000.00 |
| Jun 30, 2025 | 19,000.00 |
| Jun 30, 2025 | 19,000.00 |
| Mar 31, 2025 | 19,000.00 |
| Mar 31, 2025 | 19,000.00 |
| Dec 31, 2024 | 88,000.00 |
| Dec 31, 2024 | 88,000.00 |
| Sep 30, 2024 | 3,000.00 |
| Sep 30, 2024 | 3,000.00 |
| Jun 30, 2024 | 44,000.00 |
| Jun 30, 2024 | 44,000.00 |
| Mar 31, 2024 | 44,000.00 |
| Mar 31, 2024 | 44,000.00 |
| Dec 31, 2023 | 3,000.00 |
| Dec 31, 2023 | 3,000.00 |